October 22, 2014 10:21 PM ET


Company Overview of BioMotiv, LLC

Company Overview

BioMotiv, LLC develops medicines for patients. It develops various types of therapeutics, such as small molecules, antibodies, proteins, cell therapies, and nucleotides. The company has a strategic partnership with Takeda Pharmaceutical Company Limited. BioMotiv, LLC was formerly known as BIOU, LLC. The company was founded in 2012 and is based in Cleveland, Ohio.

3605 Warrensville Center Road

Cleveland, OH 44122-2394

United States

Founded in 2012



Key Executives for BioMotiv, LLC

Chief Executive Officer and Member of Board of Managers
Age: 42
Senior Vice President
Vice President of Business Development
Chairman of Scientific Advisory Board
Age: 65
Compensation as of Fiscal Year 2014.

BioMotiv, LLC Key Developments

Takeda Pharmaceutical Company Limited and BioMotiv, LLC Enter into Strategic Partnership

Takeda Pharmaceutical Company Limited and BioMotiv, LLC, announced that Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations. The initial investment is $25 million over five years. This investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases. Launched in 2012, The Harrington Project for Discovery & Development is a $250 million national initiative, comprising the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator. The fundamental aim is to identify, fund and rapidly advance the development of medical breakthroughs from the most innovative and respected research institutions, as well as disease foundations, throughout the USA. This initiative is unique in targeting physician-scientist discoveries and providing bench-to-bedside clinical insights into disorders where the demand for truly innovative, new medicines is paramount.

BioMotiv to Develop BioAtla's TH22 Pathway-Directed Antibody for treatment of inflammatory bowel diseases and oncologic indications

BioAtla has licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license. BioAtla used its Comprehensive Integrated Antibody Optimization (CIAO!) platform for the identification, humanization and optimization of the monoclonal antibody. The platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, providing cost and time efficiencies all through the development process. Under the deal, BioAtla will provide its discovery and preclinical development processes for the licensed compounds, while Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept.

BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM

BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM. Venue: Convene - Midtown East, 730 Third Avenue (Between East 45th and 46th Streets), 17th Floor, New York, NY 10017, United States. Speakers: Terry C. Vance, Chief Business Officer.

Similar Private Companies By Industry

Company Name Region
Selexys Pharmaceuticals Corporation United States
Incline Therapeutics, Inc. United States
Cannex Therapeutics LLC United States
Airmid Incorporated United States
Visionary Therapeutics Corporation United States

Recent Private Companies Transactions

Private Placement
September 25, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioMotiv, LLC, please visit www.biomotiv.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.